Starpharma 

$3.11
13
+$0.29+10.28%Monday 21:00

Statistics

Day High
2.82
Day Low
2.82
52W High
5.98
52W Low
2.2
Volume
1
Avg. Volume
885
Mkt Cap
1.31B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Aug 25Expected
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0
-0
0
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-64.4%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
8.07MRevenue
-5.2MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SPHRY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Lilly(Eli) &
LLY
Mkt Cap1.29T
Eli Lilly competes in the pharmaceutical sector, focusing on drugs that could directly compete with Starpharma's therapeutic products.
Pfizer
PFE
Mkt Cap164.67B
Pfizer operates in similar therapeutic areas as Starpharma, making them direct competitors in the pharmaceutical market.
Merck
MRK
Mkt Cap364.26B
Merck is involved in the development of pharmaceuticals that could compete with Starpharma's product offerings in oncology and infectious diseases.
Johnson & Johnson
JNJ
Mkt Cap687.89B
Johnson & Johnson, through its pharmaceutical division, competes across various therapeutic areas similar to Starpharma.
GSK
GSK
Mkt Cap101.13B
GlaxoSmithKline competes with Starpharma in the development and marketing of pharmaceuticals and healthcare products.
Novartis
NVS
Mkt Cap303.12B
Novartis competes in the global pharmaceutical market, offering products that could directly compete with Starpharma's portfolio.
Abbvie
ABBV
Mkt Cap521.5B
AbbVie operates in the pharmaceutical industry, focusing on areas that overlap with Starpharma's interests, such as oncology.
AMGEN
AMGN
Mkt Cap251.89B
Amgen focuses on biopharmaceuticals, competing with Starpharma in the development of novel treatments for various diseases.
Bristol-Myers Squibb
BMY
Mkt Cap129.66B
Bristol Myers Squibb competes in the pharmaceutical sector, particularly in areas like cancer treatment, which overlaps with Starpharma's focus.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG competes with Starpharma in the pharmaceutical and diagnostics market, particularly in oncology and infectious diseases.

About

Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
Show More
CEO
Cheryl Maley
Employees
50
Country
Australia
ISIN
US8555631022
WKN
000A2QE42

Listings

0 Comments

Share your thoughts

FAQs

What is Starpharma stock price today?▼
The current price of SPHRY is $3.11 USD — it has increased by +10.28% in the past 24 hours. Watch Starpharma stock price performance more closely on the chart.
What is Starpharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Starpharma stocks are traded under the ticker SPHRY.
Is Starpharma stock price growing?▼
SPHRY stock has risen by +4.71% compared to the previous week, the month change is a -40.19% fall, over the last year Starpharma has showed a +19.62% increase.
What is Starpharma market cap?▼
Today Starpharma has the market capitalization of 1.31B
When is the next Starpharma earnings date?▼
Starpharma is going to release the next earnings report on March 2, 2027.
What is Starpharma revenue for the last year?▼
Starpharma revenue for the last year amounts to 8.07M USD.
What is Starpharma net income for the last year?▼
SPHRY net income for the last year is -5.2M USD.
How many employees does Starpharma have?▼
As of November 19, 2026, the company has 50 employees.
In which sector is Starpharma located?▼
Starpharma operates in the Health & Wellness sector.
When did Starpharma complete a stock split?▼
Starpharma has not had any recent stock splits.
Where is Starpharma headquartered?▼
Starpharma is headquartered in Richmond, Australia.